The role of preoperative systemic treatment in patients with breast cancer
The goal of preoperative pharmacotherapy in patients with breast cancer is to enable breast conserving surgery in stage T3N0-1M0 or radical mastectomy in patients with primary inoperative tumors (T1-4N0-3M0). The choice of optimal treatment should be based not only on risk factors resulting from th...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2016-06-01
|
Series: | Contemporary Oncology |
Subjects: | |
Online Access: | https://www.termedia.pl/The-role-of-preoperative-systemic-treatment-in-patients-with-breast-cancer,3,27626,1,1.html |
id |
doaj-8fcdfa0394ee4f00822943dfd43c8f15 |
---|---|
record_format |
Article |
spelling |
doaj-8fcdfa0394ee4f00822943dfd43c8f152020-11-25T00:34:42ZengTermedia Publishing HouseContemporary Oncology1428-25261897-43092016-06-012029310110.5114/wo.2016.6006727626The role of preoperative systemic treatment in patients with breast cancerSylwia Dębska-SzmichMagdalena KrakowskaUrszula CzernekMaja Habib-LisikAgnieszka ZiębaPiotr PotemskiThe goal of preoperative pharmacotherapy in patients with breast cancer is to enable breast conserving surgery in stage T3N0-1M0 or radical mastectomy in patients with primary inoperative tumors (T1-4N0-3M0). The choice of optimal treatment should be based not only on risk factors resulting from the stage but also on predicted cancer responsiveness to the treatment. The breast cancer subtypes defined by immunohistochemical profile (expression of ER, PR, HER2 and Ki67) are characterized by different responsiveness to therapy. Complete response confirmed by histopathological evaluation after neoadjuvant chemotherapy is a positive prognostic factor in some breast cancer subtypes. This marker is not of value in postmenopausal patients with ER/PR+ HER2– tumors, who are candidates for neoadjuvant hormone therapy. These patients have a good prognosis if in a histopathological report after surgery there are features such as pT1, pN0, Ki67 < 3%, and ER Allred score ≥ 3. The goal of the paper is to present current knowledge about preoperative pharmacotherapy of breast cancer.https://www.termedia.pl/The-role-of-preoperative-systemic-treatment-in-patients-with-breast-cancer,3,27626,1,1.htmlpreoperative systemic treatment complete pathological response breast cancer subtypes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sylwia Dębska-Szmich Magdalena Krakowska Urszula Czernek Maja Habib-Lisik Agnieszka Zięba Piotr Potemski |
spellingShingle |
Sylwia Dębska-Szmich Magdalena Krakowska Urszula Czernek Maja Habib-Lisik Agnieszka Zięba Piotr Potemski The role of preoperative systemic treatment in patients with breast cancer Contemporary Oncology preoperative systemic treatment complete pathological response breast cancer subtypes |
author_facet |
Sylwia Dębska-Szmich Magdalena Krakowska Urszula Czernek Maja Habib-Lisik Agnieszka Zięba Piotr Potemski |
author_sort |
Sylwia Dębska-Szmich |
title |
The role of preoperative systemic treatment in patients with breast cancer |
title_short |
The role of preoperative systemic treatment in patients with breast cancer |
title_full |
The role of preoperative systemic treatment in patients with breast cancer |
title_fullStr |
The role of preoperative systemic treatment in patients with breast cancer |
title_full_unstemmed |
The role of preoperative systemic treatment in patients with breast cancer |
title_sort |
role of preoperative systemic treatment in patients with breast cancer |
publisher |
Termedia Publishing House |
series |
Contemporary Oncology |
issn |
1428-2526 1897-4309 |
publishDate |
2016-06-01 |
description |
The goal of preoperative pharmacotherapy in patients with breast cancer is to enable breast conserving surgery in stage T3N0-1M0 or radical mastectomy in patients with primary inoperative tumors (T1-4N0-3M0).
The choice of optimal treatment should be based not only on risk factors resulting from the stage but also on predicted cancer responsiveness to the treatment. The breast cancer subtypes defined by immunohistochemical profile (expression of ER, PR, HER2 and Ki67) are characterized by different responsiveness to therapy. Complete response confirmed by histopathological evaluation after neoadjuvant chemotherapy is a positive prognostic factor in some breast cancer subtypes. This marker is not of value in postmenopausal patients with ER/PR+ HER2– tumors, who are candidates for neoadjuvant hormone therapy. These patients have a good prognosis if in a histopathological report after surgery there are features such as pT1, pN0, Ki67 < 3%, and ER Allred score ≥ 3. The goal of the paper is to present current knowledge about preoperative pharmacotherapy of breast cancer. |
topic |
preoperative systemic treatment complete pathological response breast cancer subtypes |
url |
https://www.termedia.pl/The-role-of-preoperative-systemic-treatment-in-patients-with-breast-cancer,3,27626,1,1.html |
work_keys_str_mv |
AT sylwiadebskaszmich theroleofpreoperativesystemictreatmentinpatientswithbreastcancer AT magdalenakrakowska theroleofpreoperativesystemictreatmentinpatientswithbreastcancer AT urszulaczernek theroleofpreoperativesystemictreatmentinpatientswithbreastcancer AT majahabiblisik theroleofpreoperativesystemictreatmentinpatientswithbreastcancer AT agnieszkazieba theroleofpreoperativesystemictreatmentinpatientswithbreastcancer AT piotrpotemski theroleofpreoperativesystemictreatmentinpatientswithbreastcancer AT sylwiadebskaszmich roleofpreoperativesystemictreatmentinpatientswithbreastcancer AT magdalenakrakowska roleofpreoperativesystemictreatmentinpatientswithbreastcancer AT urszulaczernek roleofpreoperativesystemictreatmentinpatientswithbreastcancer AT majahabiblisik roleofpreoperativesystemictreatmentinpatientswithbreastcancer AT agnieszkazieba roleofpreoperativesystemictreatmentinpatientswithbreastcancer AT piotrpotemski roleofpreoperativesystemictreatmentinpatientswithbreastcancer |
_version_ |
1725311949615398912 |